ViaLase Closes $40M Series Funding Round
ViaLase, a clinical-stage medical technology company developing lasers for the treatment of glaucoma, has closed a $40 million series C funding round. Proceeds from the round will be used to continue commercialization of the ViaLase Laser technology including clinical, regulatory, and other commercial milestones. If approved, the ViaLase Laser will be the first femtosecond laser used for the treatment of primary open angle glaucoma, ViaLase said.
The ViaLase Laser combines femtosecond laser technology with micron-accurate image guidance for a noninvasive glaucoma treatment called femtosecond laser image-guided high-precision trabeculotomy, or FLigHT. The novel FLigHT procedure, ViaLase said, will provide physicians with precision and visibility when creating channels in the trabecular meshwork to lower intraocular pressure through a noninvasive, nonsurgical approach.
The financing was led by a new investor along with support from current investors, including Venture Investors Health Fund, Arboretum Ventures, and Falcon Vision, an ophthalmology investment platform supported by KKR.
LATEST NEWS
- LED Display Guides Surgery with Real-Time Visuals of Brain Activity
May 16, 2024
- George Mason University Receives Air Force Funding for Imaging, Digital Twins Lab
May 16, 2024
- Intel Appoints Vice President, General Manager of Foundry Arm: People in the News: 5/15/24
May 15, 2024
- Agreements Fortify NVIDIA's Role as Global Partner in Quantum Supercomputing
May 15, 2024
- Compact Single-Photon Lidar Provides High Resolution for Air and Space
May 14, 2024
- Lightium Receives $2.9M to Commercialize Data Center Tech
May 14, 2024
- Laser-Treated Cork Remedies Oil Spills Sustainably with Solar
May 13, 2024
- Optofluidic Antenna Enhances Single-Molecule Sensitivity in Liquid
May 13, 2024